Investment Pitches

Pitch Summary:
The letter highlights that Constellation’s stock has been a poor performer in 2025, hurt by weaker overall alcohol consumption and a notable decline in sales to its core Hispanic customer base. Management acknowledges the near-term pressure on results, but the manager emphasises that Constellation remains a well-run, high-quality business with strong brands and a loyal customer franchise. They note that the recent share price decline has pushed valuation to under 13x reduced earnings guidance, while the dividend yield has risen to about 3.0%.

BSD Analysis:
Constellation has had an undeniably rough stretch in 2025, and the market has wasted no time punishing it for softer alcohol consumption and a pullback from its core Hispanic consumer. Short-term pressure is real, but the reaction looks more like an overcorrection than a verdict on brand durability. This is still one of the best run portfolios in beverages, with sticky consumer loyalty and category leadership that competitors spend fortunes trying to replicate. Management isn’t sugarcoating the slowdown, which actually makes the setup cleaner because expectations have finally been reset to something realistic. The stock now trades at under 13 times reduced earnings guidance, a multiple usually reserved for businesses with far shakier fundamentals. Meanwhile, the dividend yield has quietly drifted up to roughly 3 percent, giving investors real cash return while sentiment recovers. Constellation has seen cyclical dips before, and its combination of strong brands, disciplined execution, and a loyal customer base makes it far better positioned than the recent price action implies.

Pitch Summary:
Accenture’s shares have sold off sharply due to a slowdown in client spending, reduced forward bookings, and delays/cancellations in its federal services unit, which represents about 8% of revenue. Despite these headwinds, management still projects 5%–8% earnings growth for 2026. The company has a very strong balance sheet with more cash than debt and is expected to generate close to $10 billion in free cash flow this year. It has also recently raised its dividend by 10%, bringing the yield to roughly 2.7%, and authorised an additional $5 billion share repurchase programme.

BSD Analysis:
Accenture’s selloff has all the drama of a cyclical reset but none of the hallmarks of a broken business. Clients are pulling back on discretionary projects and the federal segment is wobbling, yet even under that pressure management still expects mid-single-digit to high-single-digit earnings growth for 2026. That alone tells you how resilient the underlying model is. The balance sheet is pristine, with more cash than debt, and the company is on track to pump out close to ten billion dollars of free cash flow this year, which gives it enormous flexibility to ride out a soft demand patch. The recent ten percent dividend increase and the new five-billion-dollar buyback authorization signal that leadership sees the current weakness as temporary rather than structural. Accenture’s global scale, deep client relationships, and positioning in digital transformation give it plenty of levers once enterprise spending normalizes. The stock’s pullback looks more like an opportunity created by timing issues than a meaningful change in long-term value.

Pitch Summary:
We sold Becton Dickinson following weakness related to its recent fiscal earnings quarter, where results showed impact from cuts to certain programs funded by the National Institutes of Health (NIH). The company cut forward earnings and revenue guidance to reflect weakness in funding for biosciences research and development (R&D) and the expected impacts of tariffs. While Becton is attempting to divest its Biosciences and Diagnostic Solutions divisions, we are not confident that it will attain the best value given the cyclical downturn affecting these businesses. We believe it will take time for Becton to regain investor confidence and expand the company’s valuation.

BSD Analysis:
Aristotle Atlantic’s decision reflects a view that near-term headwinds for BD are more than just transient noise: funding pressure, portfolio complexity and execution risk on asset sales introduce downside asymmetry relative to other healthcare names. While BD remains a high-quality med-tech franchise in absolute terms, the managers see better risk-reward elsewhere, especially in companies with clearer growth trajectories and fewer moving parts. Until there is more visibility on stabilised earnings and successful portfolio optimisation, they prefer to stay on the sidelines.

Pitch Summary:
Baker Hughes is an energy technology firm with a diverse portfolio of technologies and services spanning the energy and industrial value chain. The company operates through two main segments: Industrial & Energy Technology (IET) and Oilfield Services & Equipment (OFSE). The IET segment offers a wide range of domain expertise, technologies, software and services for energy and industrial customers, including solutions for clean power, geothermal, hydrogen and emissions abatement. The OFSE segment designs and manufactures products and provides services for onshore and offshore oilfield operations, while also expanding its capabilities to address the energy transition. We believe Baker Hughes is well-positioned to capitalize on the rising global demand for natural gas and LNG projects, benefiting from its LNG franchise and critical turbomachinery. The company is also improving its margins and cash flow conversion, with EBITDA margins projected to be high teens in 2025 and targeting ~20%+ over the next few years. Additionally, Baker Hughes is accelerating its AI data center power infrastructure buildout, leveraging its NovaLT series gas turbines. The company's diversified business model, including its industrial technology arm, provides stable revenue streams. The acquisition of Chart Industries enhances its IET strategy, creating a comprehensive offering in high-growth areas. Lastly, Baker Hughes' backlog provides multi-year revenue visibility. We believe that the current valuation is attractive based on accelerating growth opportunities from the company’s IET segment and the associated higher-margin aftermarket services business.

BSD Analysis:
Aristotle Atlantic frames Baker Hughes as an energy-transition enabler with both cyclical exposure to traditional oil and gas activity and structural growth opportunities in LNG, power and decarbonisation technologies. As mix shifts toward higher-margin equipment and aftermarket services in its Industrial & Energy Technology segment, earnings quality and resilience should improve. If management continues to execute on portfolio optimisation and margin expansion, the stock could offer attractive upside from what the team views as an undemanding valuation for a high-quality energy technology franchise.

Pitch Summary:
Constellation Energy is the largest producer of carbon-free energy in the United States, operating the nation’s largest nuclear fleet alongside natural gas, geothermal, wind, solar and hydro assets. The company was spun off from Exelon in 2022 and serves over 2.5 million customers, generating revenue through a diversified mix of power generation and energy sales across regulated and deregulated power markets. The pending acquisition of Calpine will significantly expand its generation portfolio, combining 24/7 nuclear power with additional dispatchable gas capacity. Constellation is central to the U.S. energy transition and provides reliable, affordable and sustainable power critical to electrification, decarbonization and AI-driven data center growth. We see Constellation well-positioned as a leading player in the energy sector, with excellent operational performance, strong cash flow generation and significant financial flexibility. The company benefits from favorable legislation like the One Big Beautiful Bill Act, which provides tax credits for nuclear energy and support for clean hydrogen. Additionally, the company is expanding its nuclear fleet at low cost, securing long-term power purchase agreements (PPAs) with major tech companies and enhancing its asset mix through strategic acquisitions. These factors collectively validate nuclear energy as a preferred clean power source for large-scale operations and data centers. The shares of Constellation trade at a modest premium to their historical average. We view this premium as justified by the company’s clean energy profile, long-duration PPAs with hyperscalers, strong cash flow generation and leverage to the ongoing structural shift in U.S. energy demand largely driven by electrification, decarbonization and digital infrastructure investment.

BSD Analysis:
The thesis casts Constellation as a premium clean-energy platform with a unique combination of scale nuclear, diversified low-carbon assets and long-term contracted cash flows, well suited to a world of rising electricity demand and decarbonisation imperatives. While the shares trade at a modest premium to history, the managers see this as justified by its growth prospects, structural tailwinds and improved free-cash-flow profile post-Calpine. Execution on integration and regulatory risk are watchpoints, but the risk-reward remains attractive for a key beneficiary of AI and electrification trends.

Pitch Summary:
Dexcom is a medical device company specializing in continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999, the company has developed innovative technology, including a small implantable device that measures glucose levels in subcutaneous tissue and transmits data to an external receiver. The company’s products, such as the Dexcom G7 CGM system and the Stelo Glucose Biosensor, cater to both adults and children with type 1 or type 2 diabetes, as well as adults with prediabetes and type 2 diabetes who do not use insulin. Its products are marketed to healthcare professionals in the U.S. and select international markets, with the U.S. being its largest market. Our investment case for Dexcom is compelling due to its strong financial health, including a clean balance sheet and robust free cash flow generation. The company is experiencing significant growth, with organic revenue increasing in fiscal 2025 and earnings growth projected to continue over the next several years. The company is expanding its market reach with the successful launch of Stelo, a CGM for non-diabetics, and the transition to the G7 system, which offers a longer sensor life. Additionally, Dexcom is targeting the large and growing non-intensive type 2 diabetes market and continues to benefit from positive reimbursement trends. Overall, we believe this medical device company is well-positioned to capitalize on the increasing prevalence of diabetes and the growing adoption of CGM technology.

BSD Analysis:
Aristotle Atlantic views Dexcom as a high-growth, high-quality med-tech franchise with a durable competitive edge in CGM, underpinned by strong IP, scale manufacturing and deep clinical and payer relationships. As it broadens its user base beyond intensive insulin users and leverages new form factors and software features, the company could sustain elevated growth for years. Although valuation risk is inherent in a premium med-tech name, the combination of category leadership, expanding TAM and strong profitability makes Dexcom an attractive long-term compounder.

Pitch Summary:
Adaptive Biotechnologies saw accelerating momentum in its MRD (minimal residual disease) testing business with strong physician adoption trends. Average selling prices improved due to deeper clinical integration and greater value recognition by providers. Management raised full-year revenue guidance citing strong visibility in both MRD volumes and pharma partnerships. The company highlighted expanding clinical utility and the growing relevance of immune-profiling in oncology decision-making. Adaptive expects continued revenue growth driven by deeper market penetration and expanded indications.

BSD Analysis:
The thesis presents Adaptive as a leverageable platform in immune medicine with a growing annuity-like testing business, where rising volumes, improving ASPs and expanding clinical adoption can compound over time. While the company is still working toward broader profitability, the trajectory in MRD provides an increasingly solid revenue base to fund pipeline investments. Successful execution could see Adaptive evolve into a leading player at the intersection of genomics, diagnostics and immunology.

Pitch Summary:
Oracle reported momentum in its cloud business driven by strong customer demand, highlighted by a multi-year, multi-billion-dollar contract with OpenAI. Oracle’s cloud revenue growth accelerated due to increasing consumption of its Gen2 Cloud Infrastructure. The company’s remaining performance obligations (RPO) increased significantly, reflecting durable multi-year commitments from large customers. Oracle noted continued success in winning AI and cloud workloads, with a growing pipeline of enterprise migrations. Management remains confident in double-digit revenue acceleration supported by cloud demand, AI infrastructure investments and improving operational efficiency across the business.

BSD Analysis:
The manager’s thesis emphasises Oracle’s successful pivot from a legacy on-premise licence model to a cloud-centric, infrastructure and SaaS provider with growing relevance in AI-related workloads. Large, long-duration contracts and very strong RPO growth support multi-year visibility, while the scale of OCI and integration with Oracle’s enterprise stack can drive margin expansion as utilisation improves. Though competition in cloud infrastructure remains intense, Oracle’s differentiated position in database-centric and enterprise workloads provides a defensible niche with attractive economics.

Pitch Summary:
Antero Resources experienced weaker results driven by lower natural gas pricing and regional infrastructure constraints. The company faced higher volatility due to its unhedged production position relative to peers. Management noted that infrastructure bottlenecks weighed on realized prices during the quarter. However, long-term fundamentals for natural gas remain attractive given rising demand from LNG exports, industrial expansion and accelerating power needs from AI data centers. Management remains constructive on long-term supply-demand dynamics despite near-term pressure.

BSD Analysis:
Aristotle Atlantic is effectively leaning into a cyclical pullback in a structurally advantaged gas producer, arguing that today’s price and basis pressures mask a more positive multi-year outlook. Antero’s Appalachian footprint, liquids-rich resource base and leverage to growing LNG and power demand give it a robust strategic position, though investors must accept commodity-price and infrastructure risk. If gas pricing normalises and new takeaway capacity eases discounts, cash flow and equity value could inflect meaningfully higher from depressed sentiment levels.

Pitch Summary:
Darling Ingredients detracted from performance in the third quarter as uncertainty around the timelines for the U.S. Environmental Protection Agency (EPA) finalizing the proposed Renewable Volume Obligations (RVOs) weighed on sentiment. In September, there was favorable news that the EPA was proposing to reallocate some of the credits forgiven under the Small Refinery Exemption (SRE), which could raise the ultimate RVOs into next year and thus enable a more favorable backdrop for margins on renewable diesel. We believe that 2025 has played out with positive catalysts for Darling; however, the lack of finalization of the proposals led to investors being in more of a wait-and-see mode.

BSD Analysis:
The manager’s thesis frames current weakness as largely policy-timing related rather than a deterioration in Darling’s underlying competitive position, which is built on unique rendering and recycling assets and long-term relationships with customers in multiple end markets. Exposure to renewable diesel creates both upside to supportive environmental policy and some vulnerability to shifting mandates, but over the cycle this can drive attractive returns on invested capital. For investors comfortable with regulatory noise, Darling offers a differentiated, sustainability-linked growth story with significant optionality as global biofuels demand expands.

Pitch Summary:
Angi Inc. is positioned for a turnaround after a decade of strategic missteps and significant market value loss. The company has refocused on its core marketplace model, reduced unprofitable ventures, and improved operational efficiency, leading to a profitable year. With a low current valuation and potential for margin improvement, Angi offers significant upside if it continues to execute its turnaround strategy.

BSD Analysis:
Angi has undergone a significant restructuring, moving away from unprofitable ventures like fixed-price services and third-party platforms that diluted its brand and customer experience. By refocusing on its core marketplace, Angi has improved customer satisfaction and reduced churn among service providers. The company has also streamlined operations, cutting marketing and administrative costs, which has led to improved profitability. With the spin-off from IAC, Angi now has greater flexibility to pursue strategic initiatives, including share buybacks. If Angi can maintain its current trajectory and achieve growth targets, it could see a substantial increase in market valuation. However, competition from Thumbtack and potential disruptions from AI advancements remain risks to monitor.

Pitch Summary:
@DataDInvesting highlights SoFi’s Q3 as an exceptional execution quarter where nearly all of his forecasts were met with remarkable precision. The core lending engine continues to scale aggressively, particularly in personal loans, where SoFi is consolidating share through its ecosystem and underwriting advantages. Financial Services revenue is inflecting sharply as high-margin, fee-based noninterest income accelerates. The Loan Platform Business is emerging as a standout, offering capital-light, risk-free growth with strong partner demand. Credit cards appear poised for another growth leg as charge-offs normalize and new products roll out. Management execution, operating leverage, and accelerating revenue growth reinforce the bull thesis that SoFi is entering a structurally stronger growth phase.

BSD Analysis:
SoFi is transitioning from a balance-sheet-driven fintech into a diversified financial platform with multiple self-reinforcing growth engines. The LPB business meaningfully improves capital efficiency and lowers earnings volatility versus traditional consumer lenders. Industry structure favors scaled, low-cost aggregators as funding markets increasingly reward credit discipline and data-driven underwriting. SoFi’s vertically integrated tech stack and proprietary borrower funnel create barriers competitors like LendingClub and Upstart struggle to replicate. The main risks remain credit cyclicality, regulatory scrutiny, and execution risk in scaling credit cards profitably. However, improving charge-offs and rising fee-based revenue materially de-risk the model. If LPB expands into additional loan categories, earnings power could compound faster than current consensus implies.

Actual Post Content:
$SOFI hit brand new ATHs across virtually every metric in Q3. And this was by far the closest my own predictions have ever been. Here are is my deep dive earnings review. I have never had a quarter where my predictions were so close to reality. With the exception of my prediction for new members, which we’ll discuss below, the difference between what I projected and what actually happened was extremely tight, especially when it comes to originations and revenue. I honestly doubt I’ll ever have another quarter as good as this one in the future again. Regardless, 905k new members is still pretty incredible growth. They did spend slightly more per new member in sales and marketing than they have in the past, but each new member is also bringing in more revenue than they used to, so I’m ok with the extra customer acquisition cost. For everything else, I was spot on. Personal Loan Originations: $7.48B vs ($7.6B). Student Loan Originations: $1.49B vs ($1.55B). Home Loan Originations: $945M vs ($950M). Lending Revenue: $481M vs ($485M). Financial Services Revenue: $419M vs ($414M). Tech Platform Revenue: $115M vs ($116M). Corporate Revenue: -$66M vs (-$65M). Adjusted Net Revenue: $950M vs ($950M). Adjusted EBITDA: $277M vs ($294.2M). Net Income: $139.4M vs ($135.8M). EPS: $0.11 vs ($0.11). SoFi continues to absolutely own the personal loan market, has become the lending demand aggregator, and is destroying the competition. Financial services revenue growth is outstanding with fee-based noninterest income exploding. The Loan Platform Business is accelerating with a flight to quality from partners, capital-light risk-free revenue, and expanding take rates. Credit cards are ramping with improving charge-offs, and Galileo continues to underpin product velocity and margins. Revenue growth is shifting from linear to exponential.

URL: https://x.com/DataDInvesting/status/1989349737057882392